Cuprina Holdings (Cayman) Stock (NASDAQ:CUPR)

Revenue Ownership Financials Chart

Previous Close

$5.29

52W Range

$1.76 - $76.00

50D Avg

$3.45

200D Avg

$4.33

Market Cap

$13.33M

Avg Vol (3M)

$3.16M

Beta

-1.09

Div Yield

CUPR Company Profile

Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Apr 10, 2025

Website

CUPR Performance

CUPR Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$100.77K	$56.60K	$58.50K
Operating Income	$-1.07M	$-1.18M	$-552.75K
Net Income	$-1.12M	$-1.09M	$-519.69K
EBITDA	$-994.12K	$-1.06M	$-489.44K
Basic EPS	-	$-0.05	$-0.03
Diluted EPS	-	$-0.05	$-0.03

Fiscal year ends in Dec 23 | Currency in SGD

Peer Comparison

Ticker	Company
ASBP	Aspire Biopharma Holdings, Inc.
CURX	Curanex Pharmaceuticals Inc Common Stock
PCSA	Processa Pharmaceuticals, Inc.
SYBX	Synlogic, Inc.
BCTX	BriaCell Therapeutics Corp.
CRIS	Curis, Inc.
PULM	Pulmatrix, Inc.
PALI	Palisade Bio, Inc.